Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Benfotiamine vs Omega-3: Omega-3 has the stronger overall evidence (9 vs 5.5/10); they're alternatives for inflammation-related symptoms — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Omega-3 wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
2 of 2 studies with measurable effects showed benefit.
Top outcomes
Verdict
Probably helps
10 of 15 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Benfotiamine and Omega-3 have evidence — compare verdict strength side-by-side.
150-600mg daily
With meals
Benfotiamine capsules
2-3g combined EPA+DHA daily (a typical label dose, not the dose used in the cited trials, which gave 1 g or 3.25 g of omega-3 a day, or 1 to 4 g of fish oil a day without stating its EPA+DHA content)
With meals containing fat
Triglyceride form fish oil
4-12 weeks
8-12 weeks
4-8 weeks
2-4 weeks
Immediate
4-12 weeks
Vitamin B and its derivatives for diabetic kidney disease
The Cochrane database of systematic reviews (2015) · Meta analysis · n=1354
There is an absence of evidence to recommend the use of vitamin B therapy alone or combination for delaying progression of DKD.
Effect of thiamine supplementation on glycaemic outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
BMJ open (2022) · Meta analysis · n=364
Meta-analysis of 6 trials in 364 adults with type 2 diabetes given 100 to 900 mg a day of thiamine or benfotiamine for up to 3 months.
Therapeutic potential of benfotiamine and its molecular targets
European review for medical and pharmacological sciences (2018) · Systematic review
The reduction in AGEs subsequently decreases metabolic stress which benefits vascular complications seen in diabetes.
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
The New England journal of medicine (2019) · Rct · n=25871
During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24).
Omega-3 fatty acids for intermittent claudication
The Cochrane database of systematic reviews (2024) · Meta analysis · n=1830
Omega-3 compared with a control may have little to no effect on ankle-brachial index (MD -0.02, 95% CI -0.08 to 0.04; 3 studies, 168 participants; very low-certainty evidence).
A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF)
Nutritional neuroscience (2024) · Meta analysis · n=587
12 RCTs with 587 subjects: omega-3 supplementation increased serum BDNF versus placebo (SMD 0.72, 95% CI 0.28 to 1.15), with high heterogeneity (I2 = 84.39%).
The points come from one dose-comparison trial, BENDIP (PMID 18473286): 165 people with diabetic polyneuropathy randomised to 300 mg, 600 mg or placebo for 6 weeks, 133 in the ITT analysis. The Neuropathy Symptom Score differed between groups in the per-protocol analysis (p=0.033) but only narrowly missed significance by intention to treat (p=0.055), and the Total Symptom Score did not differ. Improvement was more pronounced at 600 mg, and both doses were well tolerated. No higher dose was compared, so no optimal dose can be given. The minimum effective dose comes from a separate 3-week trial of 400 mg a day in 40 inpatients, where the neuropathy score and pain improved against placebo (PMID 15726875). At 300 mg a day for 24 months, a trial in 67 people with type 1 diabetes found no effect on peripheral nerve function (PMID 22446172).
The points are the dose bands of a meta-analysis of 10 randomised trials with 1,426 adults (PMID 37028202): EPA-rich products at 1 to under 2 g of EPA a day reduced depression severity (SMD -0.43), while 2 g a day or more did not (SMD -0.20, not significant), so the 2 g point is plotted as no effect. Doses are grams of EPA, not EPA plus DHA. The Cochrane review of 33 placebo-controlled trials found a small to modest effect, unlikely to be clinically meaningful and rated very low certainty, with no difference in remission or response (PMID 34817851). No trial compared doses directly.
AI-estimated from published studies. Interpret as directional guidance.
Omega-3 has a higher evidence score (9/10 vs 5.5/10) and wins in 2 of 3 categories.
For inflammation-related symptoms, Omega-3 has a higher relevance score (85 vs 15).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The honest tier list — proven staples vs situational vs mostly marketing. The hub the other guides feed into.
On Ozempic/Wegovy/Mounjaro? What actually helps — muscle preservation, GI relief, nutrient gaps (no upsell).
Which supplements clash with blood thinners, thyroid meds, antibiotics & more — and what to do.
Caffeine+L-theanine works; bacopa needs weeks; most "brain pills" are hype. The honest tier list.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.